Healthcare provider profile · identity verified

Huey C. Lin, M.D.

Family Practice · SACRAMENTO, CA · NPI 1366428021

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	279	76
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	182	26
Amlodipine Besylate	Amlodipine Besylate	160	43
Gabapentin	Gabapentin	144	41
Levothyroxine Sodium	Levothyroxine Sodium	131	31
Losartan Potassium	Losartan Potassium	122	29
Lisinopril	Lisinopril	111	35
Eliquis	Apixaban	94	13
Metformin Hcl	Metformin Hcl	91	24
Pantoprazole Sodium	Pantoprazole Sodium	87	28
Tamsulosin Hcl	Tamsulosin Hcl	81	17
Trazodone Hcl	Trazodone Hcl	81	20
Oxycodone Hcl	Oxycodone Hcl	71	18
Furosemide	Furosemide	68	12
Duloxetine Hcl	Duloxetine Hcl	66	19
Metoprolol Succinate	Metoprolol Succinate	64	15
Albuterol Sulfate Hfa	Albuterol Sulfate	63	25
Hydrochlorothiazide	Hydrochlorothiazide	59	19
Omeprazole	Omeprazole	54	19
Sertraline Hcl	Sertraline Hcl	53	14
Carvedilol	Carvedilol	51	14
Donepezil Hcl	Donepezil Hcl	51	14
Simvastatin	Simvastatin	45	14
Diclofenac Sodium	Diclofenac Sodium	41	18
Methocarbamol	Methocarbamol	39	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	36	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	19
Metformin Hcl Er	Metformin Hcl	35	12
Potassium Chloride	Potassium Chloride	34	suppressed
Finasteride	Finasteride	33	suppressed
Jardiance	Empagliflozin	32	12
Memantine Hcl	Memantine Hcl	32	suppressed
Mounjaro	Tirzepatide	31	suppressed
Famotidine	Famotidine	28	11
Gemtesa	Vibegron	28	suppressed
Baclofen	Baclofen	27	suppressed
Clonazepam	Clonazepam	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Ozempic	Semaglutide	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	11
Atenolol	Atenolol	22	suppressed
Lidocaine	Lidocaine	21	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	20	suppressed
Prednisone	Prednisone	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Divalproex Sodium	Divalproex Sodium	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Morphine Sulfate	Morphine Sulfate	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Buprenorphine	Buprenorphine	13	suppressed
Donepezil Hcl Odt	Donepezil Hcl	13	suppressed
Levofloxacin	Levofloxacin	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Xtampza Er	Oxycodone Myristate	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Entecavir	Entecavir	12	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error